Which drug is highly in demand worldwide in the current era?
Searching the Web
most in demand drugs worldwide 2025 2026
Searching the Web
top selling pharmaceutical drugs global market 2025
Searching the Web
best selling drugs global 2026 semaglutide GLP-1
Here is a thorough breakdown of the most in-demand drugs in the current era (2025-2026):
Most In-Demand Drugs Worldwide (2026)
1. GLP-1 Receptor Agonists - The Clear #1
Semaglutide (Ozempic / Wegovy) by Novo Nordisk and Tirzepatide (Mounjaro / Zepbound) by Eli Lilly are, without question, the most in-demand drugs on the planet right now.
- The GLP-1 receptor agonist market was valued at $60.6 billion in 2025 and is projected to hit $307 billion by 2035 - a CAGR of ~17.6%
- Demand has been so overwhelming it caused multi-year global shortages
- Novo Nordisk is building a $4.1 billion manufacturing plant in North Carolina (opening ~2029) just to meet demand
- Eli Lilly has committed over $15 billion for new manufacturing plants across the US
- The drugs are used for Type 2 diabetes, obesity, and increasingly for cardiovascular protection, sleep apnea, kidney disease, and addiction research
Why so in demand?
- Global obesity rates are at record highs - over 1 billion people worldwide are obese
- These drugs produce 15-25% body weight loss, far surpassing any prior medication
- Cardiovascular and metabolic benefits beyond weight loss (reduced heart attack/stroke risk, blood pressure lowering)
- Canada has already begun approving generic semaglutide (2026), signaling massive global spread
2. Cancer Immunotherapies (Checkpoint Inhibitors)
Pembrolizumab (Keytruda) by Merck is the world's top-selling individual drug by revenue for several years running. Immune checkpoint inhibitors as a class are among the most prescribed oncology drugs globally, used across 20+ cancer types.
3. Anticoagulants
Apixaban (Eliquis) and Rivaroxaban (Xarelto) remain in extreme global demand due to the massive prevalence of atrial fibrillation, DVT, and stroke prevention needs in aging populations worldwide.
4. Antibiotics
Broad-spectrum antibiotics (amoxicillin, azithromycin, etc.) remain perennially high-demand, especially in low- and middle-income countries. Antimicrobial resistance is driving demand for newer agents.
5. COVID-19 Antivirals
Nirmatrelvir/ritonavir (Paxlovid) remains widely used, though demand has stabilized compared to the 2022-2023 peak.
Summary Table
| Drug/Class | Primary Use | Why In-Demand |
|---|---|---|
| Semaglutide / GLP-1 agonists | Obesity, Diabetes | Obesity epidemic, proven weight loss |
| Pembrolizumab (Keytruda) | Cancer | Broad oncology use, immunotherapy revolution |
| Apixaban (Eliquis) | Blood clots, AFib | Aging global population |
| Antibiotics | Infections | Universal infectious disease burden |
| Paxlovid | COVID-19 | Continued COVID circulation |
The bottom line: GLP-1 receptor agonists - particularly semaglutide and tirzepatide - are the most discussed, most prescribed, most shortage-prone, and fastest-growing drug class in the world right now. The pharmaceutical industry has not seen this level of demand for a single drug class since statins in the 1990s. Their impact is being compared to transformative moments in medical history.
This is a shared conversation. Sign in to Orris to start your own chat.